Gormley EA, Lightner DJ, Burgio KL, Chai TC, Clemens JQ, Culkin DJ, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. J Urol. 2012;188(6):2455–63.

Article  PubMed  Google Scholar 

Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology. 2003;61(1):37–49.

Article  PubMed  Google Scholar 

Krhut J, Skugarevská B, Míka D, Lund L, Zvara P. Clinical utility of β(3)-adrenoreceptor agonists for the treatment of overactive bladder: a review of the evidence and current recommendations. Res Rep Urol. 2022;14:167–75.

CAS  PubMed  PubMed Central  Google Scholar 

∙Fontaine C, Papworth E, Pascoe J, Hashim H. Update on the management of overactive bladder. Ther Adv Urol. 2021;13:17562872211039034. An excellent comprehensive review of management options

McFerren SC, Gomelsky A. Treatment of overactive bladder in the elderly female: the case for trospium, oxybutynin. Fesoterodine Darifenacin Drugs Aging. 2015;32(10):809–19.

Article  CAS  PubMed  Google Scholar 

Araklitis G, Baines G, da Silva AS, Robinson D, Cardozo L. Recent advances in managing overactive bladder. F1000Research. 2020;9:15.

Article  Google Scholar 

Powell LC, Szabo SM, Walker D, Gooch K. The economic burden of overactive bladder in the United States: a systematic literature review. Neurourol Urodyn. 2018;37(4):1241–9.

Article  PubMed  Google Scholar 

Kreydin EI, Gomes CM, Cruz F. Current pharmacotherapy of overactive bladder. Int Braz J Urol. 2021;47(6):1091–107.

Article  PubMed  PubMed Central  Google Scholar 

∙Enemchukwu EA, Subak LL, Markland A. Barriers and facilitators to overactive bladder therapy adherence. Neurourol Urodyn. 2022;41(8):1983–92. Focus on psychosocial and economic barriers to therapy and strategies to overcome these

Nitti VW, Patel A, Karram M. Diagnosis and management of overactive bladder: A review. J Obstet Gynaecol Res. 2021;47(5):1654–65.

Article  PubMed  Google Scholar 

Lightner DJ, Gomelsky A, Souter L, Vasavada SP. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment 2019. J Urol. 2019;202(3):558–63.

Article  PubMed  Google Scholar 

∙Andersson KE. Emerging drugs for the treatment of bladder storage dysfunction. Expert Opin Emerg Drugs. 2022;27(3):277–87. The best current review of recent and upcoming OAB medications with pharmacologic detail.

Nambiar AK, Arlandis S, Bø K, Cobussen-Boekhorst H, Costantini E, de Heide M, et al. European association of urology guidelines on the diagnosis and management of female non-neurogenic lower urinary tract symptoms. Part 1: diagnostics, overactive bladder, stress urinary incontinence, and mixed urinary incontinence. Eur Urol. 2022;82(1):49–59.

Article  PubMed  Google Scholar 

Payne CK. Behavioral therapy for overactive bladder. Urology. 2000;55(5):3–6 (discussion 14-6).

Article  CAS  PubMed  Google Scholar 

Pelletier EM, Vats V, Clemens JQ. Pharmacotherapy adherence and costs versus nonpharmacologic management in overactive bladder. Am J Manag Care. 2009;15(4):S108–14.

PubMed  Google Scholar 

La Rosa VL, Duarte de Campos da Silva T, Rosa de Oliveira A, Marques Cerentini T, Viana da Rosa P, Telles da Rosa LH. Behavioral therapy versus drug therapy in individuals with idiopathic overactive bladder: a systematic review and meta-analysis. J Health Psychol. 2020;25(5):573–85.

Article  PubMed  Google Scholar 

Burgio KL, Locher JL, Goode PS, Hardin JM, McDowell BJ, Dombrowski M, et al. Behavioral vs drug treatment for urge urinary incontinence in older women: a randomized controlled trial. JAMA. 1998;280(23):1995–2000.

Article  CAS  PubMed  Google Scholar 

Markland AD, Vaughan CP, Johnson TM 2nd, Burgio KL, Goode PS. Incontinence. Med Clin North Am. 2011;95(3):539–54.

Article  PubMed  Google Scholar 

Grimes WR, Stratton M. Pelvic Floor Dysfunction. StatPearls. Treasure Island (FL), StatPearls Publishing LLC. 2022.

Reisch R. Interventions for overactive bladder: review of pelvic floor muscle training and urgency control strategies. J Women’s Health Phys Therapy. 2020;44(1):19–25.

Article  Google Scholar 

Lee HE, Cho SY, Lee S, Kim M, Oh SJ. Short-term effects of a systematized bladder training program for idiopathic overactive bladder: a prospective study. Int Neurourol J. 2013;17(1):11–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mo Q, Wang Y, Ye Y, Yu J, Liu Z. Acupuncture for adults with overactive bladder: a systematic review protocol. BMJ Open. 2015;5(1): e006756.

Article  PubMed  PubMed Central  Google Scholar 

De Marco M, Arbieto ER, Da Roza TH, Resende AP, Santos GM. Effects of visceral manipulation associated with pelvic floor muscles training in women with urinary incontinence: a randomized controlled trial. Neurourol Urodyn. 2022;41(1):399–408.

Article  PubMed  Google Scholar 

Kaufman BE. An osteopathic approach to the renal and urinary system. Osteopath Family Phys. 2012;4(4):101–9.

Article  Google Scholar 

∙Cardozo LD. Biofeedback in overactive bladder. BJU Int. 2000;85(S3):24–8. An excellent resource for understanding evidence for and practices of biofeedback for OAB

Leonardo K, Seno DH, Mirza H, Afriansyah A. Biofeedback-assisted pelvic floor muscle training and pelvic electrical stimulation in women with overactive bladder: a systematic review and meta-analysis of randomized controlled trials. Neurourol Urodyn. 2022;41(6):1258–69.

Article  CAS  PubMed  Google Scholar 

Wang AC, Wang Y-Y, Chen M-C. Single-blind, randomized trial of pelvic floor muscle training, biofeedback-assisted pelvic floor muscle training, and electrical stimulation in the management of overactive bladder. Urology. 2004;63(1):61–6.

Article  CAS  PubMed  Google Scholar 

Burgio KL, Kraus SR, Johnson TM 2nd, Markland AD, Vaughan CP, Li P, et al. Effectiveness of combined behavioral and drug therapy for overactive bladder symptoms in men: a randomized clinical trial. JAMA Intern Med. 2020;180(3):411–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kasman A, Stave C, Elliott CS. Combination therapy in overactive bladder-untapped research opportunities: a systematic review of the literature. Neurourol Urodyn. 2019;38(8):2083–92.

Article  PubMed  Google Scholar 

Martin S, Han E, Gilleran J. Salvage combination therapies for refractory overactive bladder. Curr Bladder Dysfunct Rep. 2018;13:301–8.

Article  Google Scholar 

Madhuvrata P, Cody JD, Ellis G, Herbison GP, Hay-Smith EJ. Which anticholinergic drug for overactive bladder symptoms in adults. Cochrane Database Syst Rev. 2012;1:Cd005429.

PubMed  Google Scholar 

Reynolds WS, McPheeters M, Blume J, Surawicz T, Worley K, Wang L, et al. Comparative effectiveness of anticholinergic therapy for overactive bladder in women: a systematic review and meta-analysis. Obstet Gynecol. 2015;125(6):1423–32.

Article  CAS  PubMed  Google Scholar 

∙Chapple CR, Khullar V, Gabriel Z, Muston D, Bitoun CE, Weinstein D. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol. 2008;54(3):543–62. Excellent wide-reaching review of efficacy and side effects of AChs.

Gleicher S, Sebesta EM, Reynolds WS, Dmochowski R. Vibegron for the treatment of overactive bladder: a comprehensive update. Expert Opin Pharmacother. 2022;23(13):1479–84.

Article  CAS  PubMed  Google Scholar 

Suehs BT, Caplan EO, Hayden J, Ng DB, Gaddy RR. The Relationship between anticholinergic exposure and falls, fractures, and mortality in patients with overactive bladder. Drugs Aging. 2019;36(10):957–67.

Article  CAS  PubMed  Google Scholar 

Gray SL, Anderson ML, Dublin S, Hanlon JT, Hubbard R, Walker R, et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med. 2015;175(3):401–7.

Article  PubMed  PubMed Central  Google Scholar 

Ali S, Peterson GM, Bereznicki LR, Salahudeen MS. Association between anticholinergic drug burden and mortality in older people: a systematic review. Eur J Clin Pharmacol. 2020;76(3):319–35.

Article  PubMed  Google Scholar 

Linder BJ, Gebhart JB, Elliott DS, Van Houten HK, Sangaralingham LR, Habermann EB. National patterns of filled prescriptions and third-line treatment utilization for privately insured women with overactive bladder. Female Pelvic Med Reconstr Surg. 2021;27(2):e261–6.

Article  PubMed  Google Scholar 

Chua KJ, Patel HV, Tabakin A, Srivastava A, Doppalapudi SK, Hyams E, et al. Yearly trends of overactive bladder medication usage. Urology Pract. 2021;8(5):546–54.

Article  Google Scholar 

Sripad A, Raker C, Shireman T, Sung V. Overactive bladder medication prescription trends from 2014 to 2018. Neurourol Urodyn. 2022;41(3):806–12.

Article  CAS  PubMed  Google Scholar 

Cohn JA, Brown ET, Reynolds WS, Kaufman MR, Milam DF, Dmochowski RR. An update on the use of transdermal oxybutynin in the management of overactive bladder disorder. Ther Adv Urol. 2016;8(2):83–90.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Drake MJ, Chapple C, Esen AA, Athanasiou S, Cambronero J, Mitcheson D, et al. Efficacy and safety of mirabegron add-on therapy to solifenacin in incontinent overactive bladder patients with an inadequate response to initial 4-week solifenacin monotherapy: a randomised double-blind multicentre phase 3B study (BESIDE). Eur Urol. 2016;70(1):136–45.

Article  CAS  PubMed  Google Scholar 

Herschorn S, Chapple CR, Abrams P, Arlandis S, Mitcheson D, Lee KS, et al. Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study). BJU Int. 2017;120(4):562–75.

Article  CAS  PubMed